You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 113 No. 3, March 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

P. Butler, M. Mannschreck, S. Lin, I. Hwang and J. Alvarado
Department of Ophthalmology, University of California, San Francisco.

OBJECTIVE: To identify the incidence and characteristics of allergic reactions associated with the long-term use of 1% apraclonidine hydrochloride. METHODS: We undertook a retrospective analysis of 64 patients receiving long-term 1% apraclonidine therapy at the University of California-San Francisco Glaucoma Service. Patients were excluded if the duration of treatment was less than 2 weeks. Demographic data, initial intraocular pressure response, and incidence and characteristics of allergic reactions were obtained through chart review. Student's t test and chi 2 analysis were used to analyze the demographic data, and Kaplan-Meier survival analysis was used to estimate the long-term incidence of local reactions. RESULTS: Sixty-four patients met the criteria for the study. Of these, 31 (48%) developed an allergic reaction (responders) that led to discontinuation of treatment with the medication, with a mean latency of 4.7 months. Mean follow-up was 13.3 months. Patients free of local reactions (nonresponders) for at least 10 months were able to successfully continue apraclonidine use. Responders tended to be older and female. CONCLUSIONS: Our data are specific for the 1% preparation; however, physicians prescribing apraclonidine on a long-term basis should be aware of possible allergic reactions. A substantial percentage of patients developed this side effect, but most tolerated the medication for up to 4 months, and those without a local reaction after 10 months appeared to be able to continue apraclonidine use indefinitely. This allergic reaction is likely related to the adrenergic agent itself, and not to preservatives.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reduced Ocular Allergy With Fixed-Combination 0.2% Brimonidine-0.5% Timolol
Alvarado
Arch Ophthalmol 2007;125:717-717.
FULL TEXT  

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination
Larsson
Arch Ophthalmol 2001;119:492-495.
ABSTRACT | FULL TEXT  

Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion
BRITT and BURNSTINE
Br. J. Ophthalmol. 1999;83:987f-987.
FULL TEXT  

Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.